GlassScriptPhysician profile
Paul S Kim
NPI 1114923299
$31,354.80
in general payments reported to CMS, 2019-2025
72 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,728 · 2020: $1,584 · 2021: $2,306 · 2022: $2,250 · 2023: $3,066 · 2024: $3,594 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $9,659 · Long Term Medical Supply Or Device Loan: $1,196 · Education: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,000.00 |
| Food and Beverage | $9,658.85 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Education | $630.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vb Spine LLC | $12,000.00 | 2025 | Everest Spinal System |
| Novartis Pharmaceuticals Corporation | $2,283.41 | 2019-2025 | |
| Pfizer INC. | $1,915.14 | 2019-2025 | |
| Seagen INC. | $1,350.93 | 2019-2025 | Adcetris, Padcev, Tukysa |
| Janssen Biotech, INC. | $1,339.99 | 2019-2025 | Erleada, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $1,024.21 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $922.98 | 2019-2025 | Padcev, Xtandi |
| Daiichi Sankyo INC. | $762.79 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Exelixis INC. | $702.59 | 2020-2025 | Cabometyx |
| Celgene Corporation | $607.92 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Incyte Corporation | $593.66 | 2019-2025 | Jakafi, Monjuvi |
| Kite Pharma, INC. | $493.39 | 2020-2025 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $478.80 | 2019-2025 | Opdivo, Krazati, Augtyro |
| Janssen Pharmaceuticals, INC | $446.98 | 2019-2024 | Xarelto |
| Genentech USA, INC. | $443.60 | 2019-2025 | Tecentriq, Alecensa, Avastin |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $357.88 | 2022-2025 | |
| Celltrion USA INC. | $346.00 | 2023-2025 | Vegzelma |
| Rigel Pharmaceuticals, INC. | $312.43 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Astrazeneca Pharmaceuticals LP | $309.28 | 2022-2025 | Enhertu, Imfinzi, Calquence |
| Kyowa Kirin, INC. | $308.83 | 2019-2025 | Poteligeo |
| Pharmacosmos Therapeutics INC. | $300.63 | 2020-2025 | Monoferric |
| Amgen INC. | $233.06 | 2019-2022 | |
| Gilead Sciences, INC. | $232.85 | 2019-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $223.04 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $222.92 | 2019-2025 | |
| Array Biopharma INC | $215.74 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Sobi, INC | $211.30 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $171.54 | 2022-2025 | Libtayo |
| Genmab U.S., INC. | $158.93 | 2023-2025 | Epkinly, Tivdak |
| Eisai INC. | $148.17 | 2024-2025 | |
| Mirati Therapeutics, INC. | $125.61 | 2023-2024 | Krazati |
| Beigene USA, INC. | $118.94 | 2022-2025 | Brukinsa |
| Stemline Therapeutics INC. | $108.39 | 2023-2025 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $99.86 | 2019-2024 | Ninlaro, Fruzaqla |
| Beone Medicines USA, INC. | $99.22 | 2025 | Brukinsa, Tevimbra |
| Deciphera Pharmaceuticals INC. | $98.67 | 2023-2024 | Qinlock |
| Adaptive Biotechnologies Corporation | $89.75 | 2023-2024 | Clonoseq |
| Tersera Therapeutics LLC | $86.75 | 2025 | Xermelo, Zoladex |
| Caris Mpi, INC. | $86.73 | 2025 | Mi Cancer Seek |
| Geron Corporation | $82.68 | 2025 | Rytelo |
| Karyopharm Therapeutics INC. | $77.65 | 2020-2024 | Xpovio |
| Pharmaessentia USA Corporation | $76.00 | 2023-2025 | Besremi |
| Acrotech Biopharma INC. | $73.84 | 2023-2025 | Beleodaq |
| Fennec Pharmaceuticals, INC. | $70.35 | 2024-2025 | Pedmark, Fyarro |
| Servier Pharmaceuticals LLC | $70.11 | 2022-2025 | |
| Nuvasive, INC. | $67.86 | 2019 | |
| Abbvie INC. | $65.66 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $62.24 | 2022-2025 | |
| Legend Biotech USA INC. | $49.35 | 2025 | Carvykti |
| Emd Serono, INC. | $44.28 | 2025 | |
| Taiho Oncology, INC. | $44.14 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $40.06 | 2024-2025 | Enjaymo, Sylvant |
| Alexion Pharmaceuticals, INC. | $39.63 | 2019-2022 | |
| Puma Biotechnology, INC. | $39.17 | 2021-2024 | |
| Novocure INC. | $34.68 | 2020-2025 | Optune Lua (Novottf-200t) |
| Helsinn Therapeutics (U.S.), INC. | $32.14 | 2019 | |
| Morphosys, US INC. | $31.85 | 2023 | Monjuvi |
| Syndax Pharmaceuticals, INC. | $31.17 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $30.42 | 2019 | |
| Iovance Biotherapeutics, INC. | $25.23 | 2025 | Amtagvi |
| Azurity Pharmaceuticals, INC. | $24.34 | 2025 | Danziten, Vivimusta |
| Amneal Pharmaceuticals LLC | $23.96 | 2023 | Avastin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.05 | 2025 | |
| Medtronic, INC. | $21.34 | 2024 | Osteocool Rf Ablation System |
| Shield Therapeutics INC | $19.82 | 2024 | |
| Blue Earth Diagnostics | $19.78 | 2021 | |
| Myriad Genetic Laboratories, INC. | $19.42 | 2021 | |
| G1 Therapeutics, INC. | $18.51 | 2023 | Cosela |
| Springworks Therapeutics, INC. | $18.27 | 2024 | Ogsiveo |
| Insmed, INC. | $16.24 | 2025 | Arikayce |
| Pharmacyclics LLC, An Abbvie Company | $14.63 | 2020 | |
| Dova Pharmaceuticals | $14.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.